Fig. 8
From: Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Increased Notch3 and β-catenin in patient biopsy samples at the time of acquired resistance to erlotinib. a, b Pre and post EGFR TKI therapy tumor biopsies were collected and IHC analysis of Notch3 (a) and β-catenin (b) was performed
